DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Brahmer JR. et al.
Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 TPS ≥50% enrolled in KEYNOTE-024.
J Clin Oncol; 2017
35. (suppl; abstr 9000)
Access:
We do not assume any responsibility for the contents of the web pages of other providers.